Closed System Transfer Device (CSTD) can be defined as a drug transfer device that transfer medication while restricting the potential for drug contamination, exploitation, and dangerous drug exposure.
Closed System Transfer Device (CSTD) can be defined as a drug transfer device that transfer medication while restricting the potential for drug contamination, exploitation, and dangerous drug exposure. It prevents the transfer of environmental contaminants into the system, thereby preserves the quality of the solution to be injected into a patient. When the CSTD is connected to the drug vial, it balances the pressure gradient between the vessel and the syringe because imbalanced pressure can cause the fine aerosols to discharge into the air and harm patients, health care professionals, and the environment. There are two design approaches i.e. a physical barrier and an air-cleaning device that are used to prevent dangerous drugs from leaking into the environment.
The growth of the global closed system transfer devices market is attributed to increase in prevalence of cancer, rise in oncology approvals and awareness among the healthcare personnel about the safe handling of hazardous drugs. Moreover, rising technological development for safe compounding and administration of drugs is expected to drive the market growth during the forecast years.
Download Sample Report at: https://www.alliedmarketresearch.com/request-sample/11637
According to the National Institute for Occupational Safety and Health (NIOSH), closed system drug-transfer device (CSTD) is defined as a drug transfer device that mechanically prevents the transfer of environmental contaminants into the system as well as assists the escape of hazardous drug or vapor concentrations outside the system. It typically uses one of two design approaches, utilizing either a physical barrier or an air-cleaning device to prevent hazardous medications from escaping into the environment. When properly built and administered, CSTDs provide increased protection to healthcare personnel against potentially hazardous exposures during the compounding and administration of hazardous drugs.
According to the American Cancer Society data on cancer patients and their treatments, their chemotherapy treatment rates for the selected cancers included in the ACS 2019-2021 Cancer Treatment and Survivorship report estimated that approximately 62% of stage 3 and 66% of stage 4 breast cancer, similarly 75% of stage 3 and 73% of stage 4 uterus cancer are treated by chemotherapy.
According to a report published by Allied Market Research, the global closed system transfer devices market size is projected to reach $3.2 billion with a considerable CAGR from 2021 to 2030. North America is currently holding the highest market share, owing to presence of key market players, rise in prevalence of cancer cases, technological advancements, rise in government initiatives, surge in healthcare expenditure, and many other factors in the region. The Asia-Pacific region, at the same time, is expected to manifest the fastest growth rate, attributed to rise in population, increase in investment for healthcare facilities, surge in facilities providing CSTD services in the developing countries like China, India, and others.
However, the outbreak of the COVID-19 pandemic led to have a slight negative impact on the growth of the closed system transfer devices market. The implantation of global lockdown caused temporary closure to many departments in hospitals. Chemotherapy procedures were either delayed or canceled significantly, as almost all clinics and hospitals across the world were reorganized to increase the hospital capacity for COVID-19 patients. These factors hampered the growth of the market to some extent.
Nevertheless, the market is now recovering at a steady pace. With this drift on board, the key market players are investing in making of closed system transfer devices, which in turn, is going to accelerate the growth of the market even more in the upcoming years.